The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

infandx.com

Founded Year

2010

Stage

Series A - II | Alive

Total Raised

$8.34M

Last Raised

$2.2M | 2 mos ago

About InfanDx

InfanDx offers diagnostic tests for the care of neonates. Its primary focus is the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia).

InfanDx Headquarter Location

BioCampus Cologne Geb. S20 Nattermannallee 1

Koln, 50829,

Germany

+49 (0) 221 30089783

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing InfanDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InfanDx is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

InfanDx Patents

InfanDx has filed 3 patents.

The 3 most popular patent topics include:

  • Amino acids
  • Diving medicine
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/11/2017

4/26/2022

Amino acids, Diving medicine, NMDA receptor antagonists, G protein coupled receptors, Transcription factors

Grant

Application Date

9/11/2017

Grant Date

4/26/2022

Title

Related Topics

Amino acids, Diving medicine, NMDA receptor antagonists, G protein coupled receptors, Transcription factors

Status

Grant

Latest InfanDx News

Neonatal Diagnostics Company InfanDx AG Launches US Operations

Apr 12, 2022

Neonatal Diagnostics Company InfanDx AG Launches US Operations Incorporated US subsidiary & hired US VP Operations Preparing pre-submission meeting with US-FDA Received Notice of Allowance for key patent by USPTO Cologne, Germany, and Boston, MA, USA, April 12, 2022 – InfanDx AG, a privately-held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced that it has set up US operations to gain access to the US market for its HypoxE® Test. The test is designed for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) and is currently in clinical development. For the implementation of its US strategy, the Company incorporated a wholly-owned subsidiary, InfanDx USA, Inc. based in Boston, MA. Dr. Achim Plum, CEO of the parent company InfanDx AG, will serve as President of InfanDx USA, Inc. To run all US operations, InfanDx hired Mr. Jordan deVos as VP of Operations, a seasoned industry expert with a track record in clinical trial management and business development. InfanDx´ US operations will initially focus on the preparation and execution of a clinical trial for its HypoxE® Test in a US patient population to generate the data required for a planned submission to the US FDA and the potential clearance of the test. To this end, the Company has contracted GBC - Global BioClinical, a Seattle, WA, based CRO specializing in diagnostic clinical trials. Supported by US clinical experts, InfanDx USA is currently preparing the clinical trial protocol and intends to approach the US FDA for a pre-submission meeting to discuss such protocol shortly. Coinciding with the launch of its US operations, the Company received a Notice of Allowance by the USPTO for the key patent “Method of Diagnosing and Treating Asphyxia” (Patent Application Number 15/700,226). With a Notice of Allowance, the USPTO indicates its willingness to grant a patent subject to the payment of certain fees. “We are off to a very good start in implementing our US strategy. Leveraging our network in the US, we could establish our local operations very quickly by putting together a strong team that we share a lot of history with. I am very happy that we could win Jordan to head our US operations. Having worked with him before, we know that he brings exactly the expertise and network we need at this stage,” said Dr. Achim Plum, CEO of InfanDx. “We are also very pleased that we could sign-up GBC as our CRO. Again, we have successfully completed several complex diagnostics studies with Mr. Neil R. Mucci and his team at GBC in the past.”   ### About InfanDx InfanDx AG is a privately held company focusing on the development and commercialization of novel diagnostic solutions for acute and critical care conditions in newborns. The Company’s proprietary lead product in clinical development is the InfanDx HypoxE® Test designed for the reliable identification of hypoxic-ischemic encephalopathy (HIE) within the first hours of birth. HIE as a consequence of perinatal asphyxia (oxygen deficit during birth) can result in life-long disabilities. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment. However, this therapy must be initiated within six hours of birth to be effective, requiring suitable diagnostic methods to reliably and timely identify the affected newborns. While standard-of-care diagnostic methods cannot deliver a conclusive diagnosis of HIE within this time frame, the rapid InfanDx HypoxE® Test is designed to support clinicians in the timely decision whether newborns require neuroprotective hypothermia treatment. The Company is headquartered in Cologne, Germany, with a branch office in Berlin, Germany, and a wholly-owned subsidiary in Boston, MA, USA. For more information, please visit: http://www.infandx.com/

  • When was InfanDx founded?

    InfanDx was founded in 2010.

  • Where is InfanDx's headquarters?

    InfanDx's headquarters is located at BioCampus Cologne Geb. S20, Koln.

  • What is InfanDx's latest funding round?

    InfanDx's latest funding round is Series A - II.

  • How much did InfanDx raise?

    InfanDx raised a total of $8.34M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.